Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
2011

Hypoxia and Bortezomib Resistance in Chronic Myeloid Leukemia Stem Cells

publication Evidence: moderate

Author Information

Author(s): Michele Tanturli, Serena Giuntoli, Valentina Barbetti, Elisabetta Rovida, Persio Dello Sbarba

Primary Institution: Dipartimento di Patologia e Oncologia Sperimentali, Università degli Studi di Firenze

Hypothesis

The study investigates the effects of hypoxia and the proteasome inhibitor Bortezomib on the maintenance of stem or progenitor cells in Chronic Myeloid Leukemia.

Conclusion

Hypoxia-adapted leukemia stem cells in Chronic Myeloid Leukemia are completely resistant to Bortezomib.

Supporting Evidence

  • Hypoxia inhibits growth of CML cells and selects for stem cells that are resistant to Imatinib.
  • Bortezomib treatment at different times affects the viability of CML cells in hypoxia.
  • Hypoxia-selected stem cells show resistance to Bortezomib before and after their selection.

Takeaway

In a low-oxygen environment, some leukemia cells become strong and can resist treatment, making it harder to get rid of the disease.

Methodology

The study used a Culture-Repopulating Ability (CRA) assay to assess the effects of Bortezomib on K562 and primary CML cells in hypoxia.

Limitations

The study primarily focuses on in vitro conditions, which may not fully replicate in vivo environments.

Participant Demographics

The study included CD34-positive cells from blast-crisis CML patients.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0017008

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication